Overlapping Anti-NMDAR Encephalitis and Multiple Sclerosis: A Case Report and Literature Review
Front Immunol doi:10.3389/Fimmun.2023.1088801, Liu,P.,et al, 2023
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Tempo of Disease. In Merritts Neurology. Signs and symptoms in neurologic diagnosis: Approach to the patient
, Rowland, L.P.,et al, 2009
4-Aminopyridine Toxicity with Unintentional Overdose in Four Patients with Multiple Sclerosis
Neurol 71:1833-1834, Burton,J.M.,et al, 2008
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Seizures in Multiple Sclerosis
Epilepsia 42:72-79, Sokic,D.V.,et al, 2001
Clinical Presentation of Left Atrial Cardiac Myxoma
Medicine 80:159-172, Pinede,L.,et al, 2001
Multiple Sclerosis in Children Under 6 Years of Age
Neurol 53:478-484, Ruggieri,M.,et al, 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
The Phenotypic Spectrum of CADASIL:Clinical Findings in 102 Cases,
Ann Neurol 44:731-739,715, Dichgans,M.,et al, 1998
Epilepsy in Patients with Multiple Sclerosis: Radiological-Clinical Correlations
Epilepsia 39:893-896, Moreau,Th.,et al, 1998
Increased Writing Activity in Neurological Conditions:A Review and Clinical Study
JNNP 61:510-514, vanVugt,P.,et al, 1996
Periodic Lateralized Epileptiform Discharges in Multiple Sclerosis
Electroenceph Clin Neurophysiol 98:5-8, Shabolla,D.R.,et al, 1996
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Seizures Due to Multiple Sclerosis:Seven Patients with MRI Correlations
JNNP 56:1317-1320, Thompson,A.J.,et al, 1993
Suicide and Patients with Neurologic Diseases, Methodologic Problems
Arch Neurol 49:1296-1303, Stenager,E.N.&Stenager,E., 1992
Epilepsy in Multiple Sclerosis
Eur Neurol 30:218-223, Ghezzi,A.,et al, 1990
Explanation & Management of Neurological Disability
BMJ 294:1203-1205, Critchley,E.M.R.&Mitchell,J.D., 1987
Periodic Lateralized Epileptiform Discharges in a Patient with Definite Multiple Sclerosis
Clin Electroenceph 18:38-40, Awerbuch,G.I.&Verma,N.P., 1987
Prevalence and Prognosis of Epilepsy in Patients with Multiple Sclerosis
Epilepsia 27:729-733, Kinnunen,E. &Wikstrom,J., 1986
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Multiple Sclerosis with Clinical & Radiological Features of Cerebral Tumour
JNNP 45:802-808, Sagar,H.J.,et al, 1982
Intraspinal Steroid Therapy
Neurol 31:168-171, Bernat,J.L., 1981
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Central Vertigo
Otolaryn Clin North Am 6:267, Frederic,M., 1973
Narcolepsy
NEJM 288:1156, Zarcone,V., 1973
Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
JNNP 35:385, Patten,B.M.,et al, 1972
Hippus, In System of Ophthalmology
(Ed) , Vol 12 Neuro-ophthalmology C. V. Mosby Company 1971, p 637., Duke-Elder,W.S., 1971
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis
Ann Neurol 96:846-854, Marrodan,M.,et al, 2024
Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease
Ann Neurol 96:1086-1091, Fadda,G.,et al, 2024
Dramatic Response to Topiramate in Acquired Pendular Nystagmus From Multiple Sclerosis
Neurol 100:47-48, Murphy,O.C. et al, 2023
Differentiating Multiple Sclerosis from AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease with Imaging
Neurol 100:e308-e323, Cortesa,R.,et al, 2023
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis
Neurol 97:e414-e422, Jolliffe, E.A.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020